News - Boehringer Ingelheim


Current filters:

Boehringer Ingelheim

Popular Filters

101 to 125 of 167 results

New LABA/LAMA drugs set to fracture COPD market


The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Promising data on insulin degludec and LY2605541 at EASD meeting


New data presented yesterday at the Annual Meeting of the European Association for the Study of Diabetes…

Boehringer IngelheimDegludecDiabetesEli LillyLY2605541Novo NordiskPharmaceuticalResearch

Top executive appointments at Boehringer and Bristol-Myers


German family-owned drug major Boehringer Ingelheim says that Engelbert Tjeenk Willink, a member of the…

Boehringer IngelheimBristol-Myers SquibbManagementPharmaceutical

NICE final guidance backs NHS use of Boehringer Ingelheim's Actilyse


In final guidance issued this morning (September 26), UK drugs watchdog the National Institute for Health…

ActilyseBoehringer IngelheimCardio-vascularEuropePharmaceuticalPricingRegulation

Boehringer Ingelheim files first oncology compound, afatinib, for EU approval


German family-owned drug major Boehringer Ingelheim said yesterday that it has submitted a Marketing…

afatinibBoehringer IngelheimEuropeOncologyPharmaceuticalRegulation

Boehringer reveals new data on olodaterol and tiotropium combo at ERS


German family-owned drug major Boehringer Ingelheim for the first time presented data from a Phase II…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and PulmonarySpirivatiotropium

Boehringer's Spiriva has advantages for patients with COPD, says IQWiG


In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD),…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and PulmonarySpiriva

NICE issues draft guidance on Boehringer's Actilyse


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) issued draft guidance…

ActilyseBoehringer IngelheimCardio-vascularEuropePharmaceuticalRegulation

Pradaxa efficacy and cost effectiveness advantages over Xarelto


Indirect comparison based on the RE-LYtrial (for family owned German drugmaker Boehringer Ingelheim's…

BayerBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingResearchXarelto

FDA approves expanded use of Boehringer and Lilly's Tradjenta


German family-owned drug major Boehringer Ingelheim and US partner and Eli Lilly (NYSE: LLY) said on…

Boehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalRegulationTradjenta

Leading dopamine agonists will continue to dominate Parkinson's market


The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

Boehringer Ingelheim first-half 2012 sales up 6.8%


German family-owned drug major Boehringer Ingelheim yesterday reported that, for the first half of 2012,…

Boehringer IngelheimFinancialPharmaceutical

XOMA and Servier sign manufacturing deal with Boehringer for gevokizumab


US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) its partner France's Laboratoires Servier…

Boehringer IngelheimgevokizumabLicensingOphthalmicsPharmaceuticalProductionServierXOMA Corp

Boehringer and Lilly's combo diabetes drug Jentadueto gains EU approval


Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) received Marketing…

Boehringer IngelheimDiabetesEli LillyEuropeJentaduetoPharmaceuticalRegulation

Boehringer Ingelheim acquires Funxional products


German family-controlled drug major Boehringer Ingelheim has entered an agreement to acquire the global…

Anti-Arthritics/RheumaticsBoehringer IngelheimFunxional TherapeuticsFX125LLicensingPharmaceuticalRespiratory and Pulmonarysomatotaxin

Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA


US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim's Cymbalta (duloxetine)…

Boehringer IngelheimCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Boehringer Ingelheim links with Harvard for unmet medical needs research


Family-controlled German drug major Boehringer Ingelheim has established a translational research collaboration…

Antibiotics and Infectious diseasesBoehringer IngelheimOncologyPharmaceuticalResearch

More news from American Diabetes Association meeting


Ongoing news from the American Diabetes Association meeting in Philadelphia (see also The Pharma Letter…

Boehringer IngelheimDiabetesEli LillyLantusLY2605541PharmaceuticalResearchSanofi

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Boehringer Ingelheim updates US labelling of Pradaxa for stroke


Independent German drug major Boehringer Ingelheim has updated the US prescribing information for Pradaxa…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested


The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa


Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

UK academia-pharma collaboration attracts £14.4 million funding


In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

101 to 125 of 167 results

Back to top